Drug reactive metabolite-induced hepatotoxicity: a comprehensive review

References

• Abdelwahab NS, Elshemy HAH, Farid NF. 2018. Determination of flutamide and two major metabolites using HPLC-DAD and HPTLC methods. Chem Cent J. 12(1):4. doi:10.1186/s13065-018-0372-y.
   PubMedGoogle Scholar
• Aleyadeh R, Carson RP. 2020. Fosphenytoin. United States: StatPearls Publishing.
   Google Scholar
• Andrade RJ, Chalasani N, Björnsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB, Devarbhavi H, Merz M, Lucena MI, Kaplowitz N, et al. 2019. Drug-induced liver injury. Nat Rev Dis Primers. 5(1):58. doi:10.1038/s41572-019-0105-0.
   PubMed Web of Science ®Google Scholar
• Argikar UA, Cloyd JC, Birnbaum AK, Leppik IE, Conway J, Kshirsagar S, Oetting WS, Klein EC, Remmel RP. 2006. Paradoxical urinary phenytoin metabolite (S)/(R) ratios in CYP2C19*1/*2 patients. Epilepsy Res. 71(1):54–63. doi:10.1016/j.eplepsyres.2006.05.015.
   PubMed Web of Science ®Google Scholar
• Argikar UA, Remmel RP. 2009. Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 37(1):229–236. doi:10.1124/dmd.108.022426.
   PubMed Web of Science ®Google Scholar
• Barnette DA, Davis MA, Dang NL, Pidugu AS, Hughes T, Swamidass SJ, Boysen G, Miller GP. 2018. Lamisil (terbinafine) toxicity: determining pathways to bioactivation through computational and experimental approaches. Biochem Pharmacol. 156:10–21. doi:10.1016/j.bcp.2018.07.043.
   PubMed Web of Science ®Google Scholar
• Brauch H, Mürdter TE, Eichelbaum M, Schwab M. 2009. Pharmacogenomics of tamoxifen therapy. Clin Chem. 55(10):1770–1782. doi:10.1373/clinchem.2008.121756.
   PubMed Web of Science ®Google Scholar
• Bruce MA, Hall SD, Haehner-Daniels BD, Gorski JC. 2001. In vivo effect of clarithromycin on multiple cytochrome P450s. Drug Metab Dispos. 29(7):1023–1028.
   PubMed Web of Science ®Google Scholar
• Cara CJ, Pena AS, Sans M, et al. 2004. Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med Sci Monit. 10(11):RA247–RA254.
   PubMed Web of Science ®Google Scholar
• Chang M. 2012. Tamoxifen resistance in breast cancer. Biomol Ther. 20(3):256–267. doi:10.4062/biomolther.2012.20.3.256.
   PubMed Web of Science ®Google Scholar
• Chen TL, Passos-Coelho JL, Noe DA, Kennedy MJ, Black KC, Colvin OM, Grochow LB. 1995. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res. 55(4):810–816.
   PubMed Web of Science ®Google Scholar
• Colunga Biancatelli RM, Congedo V, Calvosa L, Ciacciarelli M, Polidoro A, Iuliano L. 2019. Adverse reactions of amiodarone. J Geriatr Cardiol. 16(7):552–566. doi:10.11909/j.issn.1671-5411.2019.07.004.
   PubMedGoogle Scholar
• David S, Hamilton JP. 2010. Drug-induced liver injury. US Gastroenterol Hepatol Rev. 6:73–80.
   PubMedGoogle Scholar
• Derissen EJB, Huitema ADR, Rosing H, Schellens JHM, Beijnen JH. 2018. Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2’,2’-difluorodeoxyuridine and their nucleotides. Br J Clin Pharmacol. 84(6):1279–1289. doi:10.1111/bcp.13557.
   PubMed Web of Science ®Google Scholar
• Fan-Havard P, Liu Z, Chou M, Ling Y, Barrail-Tran A, Haas DW, Taburet A-M, ANRS12154 Study Group. 2013. Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state. Antimicrob Agents Chemother. 57(5):2154–2160. doi:10.1128/AAC.02294-12.
   PubMed Web of Science ®Google Scholar
• Fohner AE, Sparreboom A, Altman RB, Klein TE. 2017. PharmGKB summary: macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics. 27(4):164–167. doi:10.1097/FPC.0000000000000270.
   PubMed Web of Science ®Google Scholar
• Ghodke Y, Anderson PL, Sangkuhl K, Lamba J, Altman RB, Klein TE. 2012. PharmGKB summary: zidovudine pathway. Pharmacogenet Genomics. 22(12):891–894. doi:10.1097/FPC.0b013e32835879a8.
   PubMed Web of Science ®Google Scholar
• Ghodke-Puranik Y, Thorn CF, Lamba JK, Leeder JS, Song W, Birnbaum AK, Altman RB, Klein TE. 2013. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 23(4):236–241. doi:10.1097/FPC.0b013e32835ea0b2.
   PubMed Web of Science ®Google Scholar
• Giancarlo GM, Venkatakrishnan K, Granda BW, von Moltke LL, Greenblatt DJ. 2001. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. Eur J Clin Pharmacol. 57(1):31–36. doi:10.1007/s002280100268.
   PubMed Web of Science ®Google Scholar
• Goda R, Nagai D, Akiyama Y, Nishikawa K, Ikemoto I, Aizawa Y, Nagata K, Yamazoe Y. 2006. Detection of a new N-oxidized metabolite of flutamide, N-[4-nitro-3-(trifluoromethyl)phenyl]hydroxylamine, in human liver microsomes and urine of prostate cancer patients. Drug Metab Dispos. 34(5):828–835. doi:10.1124/dmd.105.008623.
   PubMed Web of Science ®Google Scholar
• Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. 2002. Mechanisms of hepatotoxicity. Toxicol Sci. 65(2):166–176. doi:10.1093/toxsci/65.2.166.
   PubMed Web of Science ®Google Scholar
• Jordan VC. 2007. New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids. 72(13):829–842. doi:10.1016/j.steroids.2007.07.009.
   PubMed Web of Science ®Google Scholar
• Klein DJ, Boukouvala S, McDonagh EM, Shuldiner SR, Laurieri N, Thorn CF, Altman RB, Klein TE. 2016. PharmGKB summary: isoniazid pathway, pharmacokinetics. Pharmacogenet Genomics. 26(9):436–444. doi:10.1097/FPC.0000000000000232.
   PubMed Web of Science ®Google Scholar
• Klein DJ, Thorn CF, Desta Z, Flockhart DA, Altman RB, Klein TE. 2013. PharmGKB summary: tamoxifen pathway, pharmacokinetics. Pharmacogenet Genomics. 23(11):643–647. doi:10.1097/FPC.0b013e3283656bc1.
   PubMed Web of Science ®Google Scholar
• Kostrubsky SE, Strom SC, Ellis E, Nelson SD, Mutlib AE. 2007. Transport, metabolism, and hepatotoxicity of flutamide, drug-drug interaction with acetaminophen involving phase I and phase II metabolites. Chem Res Toxicol. 20(10):1503–1512. doi:10.1021/tx7001542.
   PubMed Web of Science ®Google Scholar
• Lowenberg D, Thorn CF, Desta Z, Flockhart DA, Altman RB, Klein TE. 2014. PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 24(2):133–138. doi:10.1097/FPC.0000000000000019.
   PubMed Web of Science ®Google Scholar
• Naveen BK, Siva RC, Vara PS, Tanvija K, Vyshnavi T, Sirisha K, Ravindra BP. 2023. Hepatoprotective activity of herbal extracts and other compounds against acetaminophen-induced hepatotoxicity by various mechanisms: a narrative review. Ann. Phytomed. 12(2):70–88. doi:10.54085/ap.2023.12.2.9.
   Web of Science ®Google Scholar
• Pachot JI, Botham RP, Haegele KD, Hwang K. 2003. Experimental estimation of the role of P-Glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. J Pharm Pharm Sci. 6(1):1–12.
   PubMed Web of Science ®Google Scholar
• Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, Williams DP. 2005. The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol. 45(1):177–202. doi:10.1146/annurev.pharmtox.45.120403.100058.
   PubMedGoogle Scholar
• Patel JM. 1990. Metabolism and pulmonary toxicity of cyclophosphamide. Pharmacol Ther. 47(1):137–146. doi:10.1016/0163-7258(90)90049-8.
   PubMed Web of Science ®Google Scholar
• Perez MJ, Briz O. 2009. Bile-acid-induced cell injury and protection. World J Gastroenterol. 15(14):1677–1689. doi:10.3748/wjg.15.1677.
   PubMed Web of Science ®Google Scholar
• Pessayre D, Fromenty B, Berson A, Robin M-A, Lettéron P, Moreau R, Mansouri A. 2012. Central role of mitochondria in drug-induced liver injury. Drug Metab Rev. 44(1):34–87. doi:10.3109/03602532.2011.604086.
   PubMed Web of Science ®Google Scholar
• Qin C, Yang G, Yang J, Ren B, Wang H, Chen G, Zhao F, You L, Wang W, Zhao Y, et al. 2020. Metabolism of pancreatic cancer: paving the way to better anticancer strategies. Mol Cancer. 19(1):50. doi:10.1186/s12943-020-01169-7.
   PubMed Web of Science ®Google Scholar
• Quaglino D, Ha HR, Duner E, Bruttomesso D, Bigler L, Follath F, Realdi G, Pettenazzo A, Baritussio A. 2004. Effects of metabolites and analogs of amiodarone on alveolar macrophages: structure-activity relationship. Am J Physiol Lung Cell Mol Physiol. 287(2):L438–L447. doi:10.1152/ajplung.00434.2003.
   PubMed Web of Science ®Google Scholar
• Ramachandran G, Swaminathan S. 2012. Role of pharmacogenomics in the treatment of tuberculosis: a review. Pharmgenomics Pers Med. 5:89–98. doi:10.2147/PGPM.S15454.
   PubMedGoogle Scholar
• Russmann S, Kullak-Ublick GA, Grattagliano I. 2009. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem. 16(23):3041–3053. doi:10.2174/092986709788803097.
   PubMed Web of Science ®Google Scholar
• Saif MW, Lee Y, Kim R. 2012. Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer. Ther Adv Med Oncol. 4(6):341–346. doi:10.1177/1758834012453755.
   PubMed Web of Science ®Google Scholar
• Saito H, Fukasawa Y, Otsubo Y, Yamada K, Sezaki H, Yamashita S. 2000. Carrier-mediated transport of macrolide antimicrobial agents across Caco-2 cell monolayers. Pharm Res. 17(6):761–765. doi:10.1023/a:1007550820196.
   PubMed Web of Science ®Google Scholar
• Schuetz EG, Beck WT, Schuetz JD. 1996. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 49(2):311–318.
   PubMed Web of Science ®Google Scholar
• Steinbrecht S, Kiebist J, König R, Thiessen M, Schmidtke K-U, Kammerer S, Küpper J-H, Scheibner K. 2020. Synthesis of cyclophosphamide metabolites by a peroxygenase from Marasmius rotula for toxicological studies on human cancer cells. AMB Express. 10(1):128. doi:10.1186/s13568-020-01064-w.
   PubMed Web of Science ®Google Scholar
• Thorn CF, Whirl-Carrillo M, Leeder JS, Klein TE, Altman RB. 2012. PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 22(6):466–470. doi:10.1097/FPC.0b013e32834aeedb.
   PubMed Web of Science ®Google Scholar
• Timm R, Kaiser R, Lötsch J, Heider U, Sezer O, Weisz K, Montemurro M, Roots I, Cascorbi I. 2005. Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. Pharmacogenomics J. 5(6):365–373. doi:10.1038/sj.tpj.6500330.
   PubMed Web of Science ®Google Scholar
• Usman M, Zhen-Han Z, Ze-Na C, Jun-Ping H, Wen Q, Chang-Qing Y, Miyu N, Toshiyuki S. 2019. Effect of Iguratimod on diclofenac metabolism by CYP2C9 in rats and human recombinant CYP2C9 yeast cells. Braz J Pharm Sci. 55:e17240. doi:10.1590/s2175-97902019000117240.
   Web of Science ®Google Scholar
• Vasta LM, Zanetti RC, Parekh DS, Warwick AB, Lieuw K. 2021. A retro­spective review of mercaptopurine metabolism reveals high rate of patients with suboptimal metabolites successfully corrected with allopurinol. J Pediatr Hematol Oncol. 43(7):e1003–e1009. doi:10.1097/MPH.0000000000001939.
   PubMed Web of Science ®Google Scholar
• Zhang J, Tian Q, Zhou SF. 2006. Clinical pharmacology of cyclophosphamide and ifosfamide. CDTH. 1(1):55–84. doi:10.2174/157488506775268515.
   Google Scholar